December 23, 2025 — We strongly suspect that advanced oral obesity medicines may be a defining milestone for 2026. This is because they have the potential to fill an important gap in obesity therapy – the unmet need for therapies that people can persistently take to maintain control of this chronic disease. Late yesterday, FDA granted approval for the […]
December 20, 2025 — News from Lilly about orforglipron this week points to what might be the next big development for GLP-1 medicines. The company announced topline results for a weight maintenance study of orforglipron and this first glimpse has us thinking that maintain might be the magic word in obesity care next year. The topline come from the […]
December 15, 2025 — Business is apparently booming in the criminal trade for bogus obesity medicines. The Times (London) reports that criminals are selling dangerous weight-loss jabs on social media and in gyms. They write that: “Pharmaceutical bosses have issued a stark warning about medicines such as Mounjaro sold online without safety controls as gangs branch out from hard […]
December 12, 2025 — “I am over the moon about this,” said Harvard professor Caroline Apovian to us. She was talking about the outstanding topline results with retatrutide reported by Lilly from a phase three study. This is the so-called triple-G agonist that first stunned the world with its phase two results two years ago. In the results yesterday, […]
December 3, 2025 — As the world is coming around to the understanding that public health policy cannot neglect the need for obesity treatment, a question hangs in the air. What does this mean for obesity prevention strategies? This question – together with fast-changing market realities – begs another question. Will prevention policy or market dynamics reduce obesity more? […]
December 2, 2025 — This is huge news and we’ve been waiting for it a very long time. For the first time ever, the World Health Organization (WHO) is embracing obesity treatment in a new global guidance issued yesterday. From the head of WHO, Director-General Tedros Adhanom Ghebreyesus, came words we wondered if we would ever hear: “Our new […]
November 26, 2025 — It seems like some good news is overdue for Novo Nordisk. So the topline report of a phase two study with amycretin that looks like a plausible win is especially welcome. The results at hand come from a 36-week placebo controlled study with a wide range of oral and injection doses in persons with type […]
November 21, 2025 — The sprint to the finish for orforglipron is picking up pace with a pivotal trial in obesity and diabetes published yesterday in The Lancet. Things are looking good for this relatively simple GLP-1 agonist in a tablet. The presentation of these results from ATTAIN-2 were a highlight of ObesityWeek earlier this month, but having this […]
November 15, 2025 — Anyone who thought this would be a passing thing was way off the mark. As prices of GLP-1 medicines are falling, their use is rising. As Stat News notes, we now have more people using these medicines than the entire population of Texas. This rising trend occurs against a background of costs that are still […]
November 12, 2025 — This is a perilous and exciting time for investing in obesity innovation as the market for treating this disease advances dramatically. On the side of excitement, we note that the David Wainer in the Wall Street Journal predicts that “obesity drugs are about to go mass market.” Perilous for Novo On the side of peril, […]
